V114 is Comparable to PCV13 in Protection Against Pneumococcal Disease
The immune response of all 15 serotypes in the V114 pneumococcal vaccination were higher than those in the PCV13 vaccination.
The administration of V114, a 15-valent pneumococcal conjugated vaccine (PCV), had a comparable number of antibody levels compared to PCV13, 12-valent, followed by a 23-valent pneumococcal polysaccharide vaccine in adults 50 years of age or older, according to the results of a study published by Vaccine.
Thirty days after vaccination, the immune response to serotype 3, which is the most common serotype of pneumococcal disease, was higher in the V113 group than the PCV13 group, whereas serotype 4 was slightly lower.
Also, all 15 serotypes in the vaccine induced an immune response that was higher for the serotypes unique to V114 than in PCV13 and were comparable for the 13 shared serotypes.
The opsonophagocytosis (OPA) titers and immunoglobulin G (IgG) response declined between day 30 and month 12 but were still higher than at day 1 for both V114 and PCV13. The antibody protection for up to 12 months post-vaccination was comparable between the shared serotypes in both vaccines, according to the study.
The administration of PPSV23 following V114 elicited an immune response to all 15 serotypes. OPA IgG responses 30 days after the PPSV23 vaccine was administered were comparable to the serotypes’ levels 30 days after the PCV vaccination, according to the study.
Serum samples of the individuals were collected before the PCV vaccine on day 1, 30 days after the PCV vaccination, before the PPSV23 vaccination at 12 months, and 30 days after the PPSV23 vaccination.
The study was conducted from June 2018 to December 2019 at 22 sites including, in the United States, Republic of Korea, Spain, and Taiwan. There were 600 individuals in the study who received either the V114 or PCV13 vaccine on a 1 to 1 basis, followed by the PPSV23 vaccination 12 months later.
The individuals enrolled in the study were 50 years of age or older and generally in good health and/or had stable underlying medical conditions.
Approximately 1 to 5 days after the vaccination, injection-site reactions such as erythema, swelling, and pain occurred. From 1 to 14 days after the vaccination, muscle pain, joint pain, headache, and fatigue could occur, according to the study.
Reference
Song J, Chang, C, Andrews C, Diez-Domingo J, et al. Safety, tolerability, and immunogenicity of V114, a 15 valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: a randomized phase III trial (PNEU-PATH). Vaccine. 2021;S0264-410X(21)01071-9 doi:10.1016/j.vaccine.2021.08.038
